Роль патогенетической терапии болезни Альцгеймера в снижении нагрузки на лиц, ухаживающих за пациентами
Игорь Владимирович Колыхалов, Г А Рассадина · Современная терапия в психиатрии и неврологии · 2012
The efficacy and safety of four-month courses of rivastigmine and changes in measures of caregivers burden were studied in a non-randomized group of 25patients with Alzheimers disease (AD). All patients received p.o. rivastigmine and 22patients received antipsychotic therapy along with rivastigmine on admission. Result of the study showed that the use of rivastigmine in AD patients with behavioral and psychotic disorders at the stage of moderately severe dementia not only improved the patients cognitive functions, but also had positive effects in terms of decreasing psychotic and behavioral disorders. Inclusion of rivastigmine in the complex treatment of AD patients led to significant decreases in the doses of psychotropic drugs, and in some patients to complete withdrawal of all antipsychotics. It is extremely important to emphasize that the use of rivastigmine in patients with moderately severe AD and behavioral disorders led to significant (up to 30%) decreases in the caregivers time spent on the care and supervision of the patients, along with decreases in the level of stress and improvements in the health of caregivers, indicating increases in the quality of life of both patients and their families.
Cited by 0 works.